Search





Search





Markets
/
Stocks
/
nasdaq-cycn
/

Cyclerion Therapeutics Inc

CYCN

Add to Watchlist

3.110USD

+0.020+0.65%

Market hours （ET）Quotes delayed by 15 min

13.19MMarket Cap

LossP/E TTM



Cyclerion Therapeutics Inc

3.110

+0.020+0.65%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cyclerion Therapeutics Inc

Currency: USD Updated: 2026-05-14

Key Insights

Cyclerion Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 193 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 8.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cyclerion Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

193 / 382

Overall Ranking

366 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cyclerion Therapeutics Inc Highlights

StrengthsRisks

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.07M.

Undervalued

The company’s latest PE is -2.37, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 318.08K shares, decreasing 67.72% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.93.

Analyst Rating

Based on 0 analysts

Current Rating

8.000

Target Price

+155.59%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-14

The current financial score of Cyclerion Therapeutics Inc is 9.05, ranking 15 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 122.32%.

Score

Industry at a Glance

Previous score

9.05

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.45

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cyclerion Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-14

The current valuation score of Cyclerion Therapeutics Inc is 7.13, ranking 158 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.37, which is -553.03% below the recent high of 10.72 and -143.05% above the recent low of -5.75.

Score

Industry at a Glance

Previous score

7.13

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 193/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-14

No earnings forecast score is currently available for Cyclerion Therapeutics Inc. The Biotechnology & Medical Research industry's average is 8.13.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-14

The current price momentum score of Cyclerion Therapeutics Inc is 6.64, ranking 220 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.45 and the support level at 2.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.74

Change

-0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.092

Neutral

RSI(14)

51.952

Neutral

STOCH(KDJ)(9,3,3)

33.502

Sell

ATR(14)

0.180

High Vlolatility

CCI(14)

-31.558

Neutral

Williams %R

61.326

Sell

TRIX(12,20)

0.465

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

3.138

Sell

MA10

3.175

Sell

MA20

3.116

Sell

MA50

2.641

Buy

MA100

2.011

Buy

MA200

2.074

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-14

The current institutional shareholding score of Cyclerion Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 7.35%, representing a quarter-over-quarter decrease of 69.12%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Hecht (Peter M)

559.20K

J. Wood Capital Advisors LLC

181.82K

American Endowment Foundation

133.03K

Invus Public Equities Advisors, LLC

115.60K

-0.48%

Two Sigma Investments, LP

69.86K

+425.50%

Graul (Regina Margaret)

55.78K

-44.39%

De Souza (Errol B)

50.00K

Geode Capital Management, L.L.C.

43.30K

+16.53%

Higgins (Michael J)

30.74K

+5.67%

Hyman (Steven)

20.00K

Risk Assessment

Currency: USD Updated: 2026-05-14

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cyclerion Therapeutics Inc is 1.54, ranking 292 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.82. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.